Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-3201 Phase I Trial in Healthy Participants
NCT07889349Phase 1Not yet recruiting
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd.
- Start
- Nov 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR-3201 in Alzheimer's disease (AD) (5 arms), sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Primary endpoint: Adverse Events. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
SHR-3201
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07889349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07889349.